First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE(2)-receptor E-type 4 (EP4), in patients with advanced cancers

BACKGROUND: E7046 is a highly selective, small-molecule antagonist of the E-type prostanoid receptor 4 (EP4) for prostaglandin E2, an immunosuppressive mediator of the tumor immune microenvironment. This first-in-human phase 1 study assessed the safety, tolerability, pharmacokinetics, pharmacodynami...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, David S, Parikh, Aparna, Shapiro, Geoffrey I, Varga, Andrea, Naing, Aung, Meric-Bernstam, Funda, Ataman, Özlem, Reyderman, Larisa, Binder, Terri A, Ren, Min, Liu, Mingjie, Dayal, Satish, Siu, Amy Y, Sachdev, Pallavi, Xu, Lucy, Bhagawati-Prasad, Vijay, Tchakov, Ilian, Ooi, Chean Eng, Bao, Xingfeng, Marabelle, Aurelien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304851/
https://www.ncbi.nlm.nih.gov/pubmed/32554609
http://dx.doi.org/10.1136/jitc-2019-000222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304851/
https://www.ncbi.nlm.nih.gov/pubmed/32554609
http://dx.doi.org/10.1136/jitc-2019-000222

Ejemplares similares